Bone Biologics Corporation (BBLG)

Bone Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.53	5.33	3.33	3.03	7.54	6.68
Cash & Short-Term Investments	4.53	5.33	3.33	3.03	7.54	6.68
Cash Growth	64.94%	60.42%	9.87%	-59.85%	12.93%	-
Other Receivables	0.01	0.01	-	-	-	-
Total Trade Receivables	0.01	0.01	-	-	-	-
Other Current Assets	0.44	0.45	0.54	0.71	0.96	-
Total Current Assets	4.98	5.8	3.86	3.74	8.5	6.68
Total Assets	4.98	5.8	3.86	3.74	8.5	6.68
Accounts Payable	0.31	0.42	0.37	0.36	0.1	0.1
Unearned Revenue	-	-	-	-	0.78	-
Other Current Liabilities	0	0	0	0.47	1.66	-
Total Current Liabilities	0.31	0.42	0.38	0.83	2.55	0.1
Total Liabilities	0.31	0.42	0.38	0.83	2.55	0.1
Common Stock	0	0	0	0	0	0.01
Additional Paid-in Capital	93.56	93.51	88.5	83.81	77.91	77.04
Retained Earnings	-88.9	-88.13	-85.02	-80.91	-71.96	-70.48
Shareholders' Equity	4.67	5.38	3.48	2.91	5.95	6.58
Total Liabilities & Equity	4.98	5.8	3.86	3.74	8.5	6.68
Net Cash (Debt)	4.53	5.33	3.33	3.03	7.54	6.68
Net Cash Growth	-15.08%	60.42%	9.87%	-59.85%	12.93%	-
Net Cash Per Share	3.04	4.54	13.14	69.01	949.05	2109.57
Book Value	4.67	5.38	3.48	2.91	5.95	6.58
Book Value Per Share	3.14	4.58	13.77	66.27	748.75	2077.99
Tangible Book Value	4.67	5.38	3.48	2.91	5.95	6.58
Tangible Book Value Per Share	3.14	4.58	13.77	66.27	748.75	2077.99

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q